Since immunotherapy resistance is an increasing therapeutic challenge in cancer, including melanoma, we set up an experimental system to model T cell resistance, similar to what we and others have done successfully previously to study BRAF + MEK resistance26. Here, MAP2K7 is linked to melanoma.